104 related articles for article (PubMed ID: 16762510)
21. Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2.
Berardi R; Maccaroni E; Onofri A; Giampieri R; Pistelli M; Bittoni A; Scartozzi M; Pierantoni C; Mandolesi A; Bearzi I; Cascinu S
Expert Opin Pharmacother; 2009 Oct; 10(15):2467-78. PubMed ID: 19761354
[TBL] [Abstract][Full Text] [Related]
22. [Molecular mechanisms in the development and progression of pancreas and biliary tract cancers].
Ohashi K; Nakajima Y
Nihon Rinsho; 2007 Jan; 65(1):165-74. PubMed ID: 17233433
[TBL] [Abstract][Full Text] [Related]
23. NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
Kiesslich T; Mayr C; Neureiter D
EBioMedicine; 2019 Nov; 49():9-10. PubMed ID: 31648982
[No Abstract] [Full Text] [Related]
24. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
Li Y; Li W; Yang Y; Lu Y; He C; Hu G; Liu H; Chen J; He J; Yu H
Brain Res; 2009 Aug; 1286():13-8. PubMed ID: 19559015
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer chemotherapy in the era of targeted therapy.
Michael A; Syrigos K; Pandha H
Prostate Cancer Prostatic Dis; 2009; 12(1):13-6. PubMed ID: 18521103
[TBL] [Abstract][Full Text] [Related]
26. [Surgical outcome of biliary tract cancer with postoperative chemotherapy].
Sugawara G; Ebata T; Yokoyama Y; Igami T; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1483-5. PubMed ID: 23130375
[No Abstract] [Full Text] [Related]
27. Utilization of genomic signatures to direct use of primary chemotherapy.
Potti A; Nevins JR
Curr Opin Genet Dev; 2008 Feb; 18(1):62-7. PubMed ID: 18339540
[TBL] [Abstract][Full Text] [Related]
28. New molecular targets and novel agents in the treatment of advanced urothelial cancer.
Beekman KW; Bradley D; Hussain M
Semin Oncol; 2007 Apr; 34(2):154-64. PubMed ID: 17382799
[TBL] [Abstract][Full Text] [Related]
29. [Breast cancer and molecular markers].
Ishioka C
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1261-8. PubMed ID: 18701834
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.
Mathew J; Asgeirsson KS; Cheung KL; Chan S; Dahda A; Robertson JF
Eur J Surg Oncol; 2009 Feb; 35(2):113-22. PubMed ID: 18502088
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy and histological stratification of biliary tract cancers.
Cariati A; Piromalli E
Oncology; 2012; 82(6):352-3. PubMed ID: 22677952
[No Abstract] [Full Text] [Related]
35. Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines.
Takahashi T; Saikawa Y; Nakamura R; Kumagai K; Takeuchi H; Kubota T; Kitagawa Y
Oncol Rep; 2009 Feb; 21(2):451-9. PubMed ID: 19148522
[TBL] [Abstract][Full Text] [Related]
36. [Surgical outcome of biliary tract cancer with neoadjuvant chemotherapy].
Kato A; Shimizu H; Yoshidome H; Otsuka M; Furukawa K; Yoshitomi H; Takeuchi D; Takayashiki T; Kuboki S; Suzuki D; Nakajima M; Miyazaki M
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1486-9. PubMed ID: 23133873
[No Abstract] [Full Text] [Related]
37. Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.
Hopfner M; Schuppan D; Scherubl H
World J Gastroenterol; 2008 Dec; 14(46):7021-32. PubMed ID: 19084910
[TBL] [Abstract][Full Text] [Related]
38. The role of novel biologics in biliary cancers.
Jordan E; Braghiroli MF; Lowery MA
Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
[TBL] [Abstract][Full Text] [Related]
39. Drug development and clinical trial design in pancreatico-biliary malignancies.
Harrington J; Carter L; Basu B; Cook N
Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439
[TBL] [Abstract][Full Text] [Related]
40. [Development for combination of surgery and chemotherapy on biliary tract cancer].
Kato A; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Furukawa K; Yoshitomi H; Mitsuhashi N; Takeuchi D; Takayashiki T; Suda K; Takano S; Miyazaki M
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1685-89. PubMed ID: 18975457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
